SCHEMBL5465503

SCHEMBL5465503

CCOc1ccc(Cl)cc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ncc(Cl)cc3Cl)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
LMNA P02545 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
HPGD P15428 2/20 0.53
MAPK1 P28482 2/20 0.53
RBP4 P02753 3/20 0.50
ALK Q9UM73 1/20 0.49
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
P2RY12 Q9H244 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
NPC1 O15118 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KDM4E B2RXH2 1/20 0.45
CA12 O43570 1/20 0.45
CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451470 0.93 MAPT (0.49) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5460920 0.92 KMT2A (0.56) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5459445 0.88 RBP4 (0.54) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5463477 0.86 TRPV1 (0.53) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5465926 0.85 RBP4 (0.51) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5469328 0.85 MAPT (0.56) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5469339 0.84 RBP4 (0.50) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5458239 0.81 MAPT (0.52) MAPTLMNASMN1; SMN2HPGDMAPK1
SCHEMBL5464810 0.80 KMT2A (0.54) MAPTLMNASMN1; SMN2ALDH1A1MEN1
SCHEMBL5473080 0.80 SMN1; SMN2 (0.55) MAPTLMNASMN1; SMN2HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885LMNA 3721/4885SMN1; SMN2 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.